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two groups. Analyzing separately subgroups of men and women 
showed that men lost their weigh independently from the fact of 
getting personal genetic cardiovascular risk estimates (1.5 kg and 1.8 
kg in groups 1 and 2 accordingly), while women reduced their weight 
mainly in the group with genetic testing - 4.2 kg compared to control 
group who lost 0.8 kg. Conclusions: Our data reports that there can be 
gender-specific reaction to genetic testing. It was shown in previous 
studies that women in our population have more positive attitudes and 
beliefs to predictive genetic testing.
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Medical genetics has made significant progress in the last decades, 
especially in the field of prenatal testing. After the dramatic expansion 
of prenatal diagnosis that started in the seventies, pre-implantation 
genetic diagnosis (PGD) became a reality in 1990, following 
advances in the techniques of medically assisted reproduction 
(MAR). Ethical problems related to this technique start well before 
the analysis: it is necessary to offer appropriate genetic counselling, 
to obtain informed consent for the necessary procedures and to 
maintain strict confidentiality of the whole process. The main ethical 
problems concern the status of the embryo, the investigation and the 
manipulation of embryos, eugenic or sex selection and the provision of 
resources. In 2000 a questionnaire addressing several of the principal 
ethical concerns, namely the attitude towards PGD, embryos and 
genetic testing, was distributed to the Directors of the five largest MAR 
centres in Portugal; in 2010 the same questionnaire was sent to 27 
MAR centres and answered by 11. In all cases it was required that 
the answers should be based on the general policy of each centre. 
This work presents the comparative analysis of all the obtained data, 
particularly focusing on the main ethical problems related to this 
diagnosis, i.e., the status of the human embryo and the attitude of 
the genetic professionals working in this still relatively new, and very 
specific, field of genetic diagnosis.
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In general, prenatal test is recognized as population screening in many 
countries. For example, more than 80% women have maternal serum 
test as screening in the UK. In Japan, we do not offer maternal serum 
test as screening in most obstetrics services. We might provide the 
information of screening test and further chromosomal test such as 
CVS and amniocentesis with the information of genetic counselling. 
There is no regulation for prenatal diagnosis in ultrasound diagnosis, 
so some clinic would offer screening at some point and some do not. 
We do not scan the fetus as screening without patient’s request at our 
hospital.
Historically, we have been concerned with prenatal diagnosis over 30 
years at our hospital. At first, we had been doing only the test and 
given the result for referred patients; however we now offer genetic 
counselling for referred patients to avoid automatic screening and to 
have informed choice for prenatal diagnosis.
Prenatal diagnosis contains ethical issues all the time, but most 
pregnant women do not notice this problem until they consider 
termination at some point. Genetic counselling in prenatal diagnosis 
could be good support for the patient who has to face difficult ethical 
issues during pregnancy. It sometimes reduces unnecessary risk for 
worries and/or invasive test.
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Among current teenagers we find a large proportion of future parents, 
some of whom will be seeking prenatal genetic counseling. Getting 
raised in the genomic era may not only increase the knowledge of 
available genetic testing but may also have an impact on how genetic 
information is perceived. However, little is known about how this 
teenage group reacts to the language commonly used by health 
care professionals providing prenatal counseling. In addition, as risk 
communication is related to numbers and figures, having different 
educational backgrounds may be associated with separate risk 
perceptions. In order to investigate these issues, a previously developed 
questionnaire (Abramsky & Fletcher, 2002) was administered to 
high-school students in Sweden. A total of 344 questionnaires were 
completed by students belonging to a natural science or a social 
science program. Our data show that teenage participants were 
particularly worried by the use of technical jargon and words like rare 
and abnormal. Negative framing effects and perception differences 
related to numeric risk formats were also present. There were some 
cases of gender and educational program effects on risk assessment 
but this outcome was not generalizable. Besides the questionnaire 
results, we discuss the ethical implications of the data based on the 
norm of non-directiveness and try to provide some basic guidelines. In 
general, genetic counselors should be aware that the language used 
within clinical services can be influential on this group of upcoming 
counselees.
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Background: In the Netherlands, expensive medicines are not 
reimbursed for off-label use without sufficient evidence of efficacy. 
Patients with rare diseases are disadvantaged because the burden 
of proof is difficult to meet. There are obstacles both for industry and 
academia to performing large-scale randomized, controlled trials. 
Moreover, reimbursement rules discourage doctors from prescribing 
expensive medicines off-label, even to small groups of patients. 
Examples of reimbursement problems with off-label medicines are 
known from many rare disease areas, including genetic disease. 
Controlled n-of-one (single-patient) trials with internal randomisation 
(e.g. AB-BA-BA) could generate new evidence for rare, chronic 
conditions where the aim of treatment is symptom control.
Objective: This project aims to initiate development of an n-of-
one trial service, embedded in the Dutch health care system. Pilot 
implementation will be designed, focusing on neuromuscular diseases 
as a model.
methods: Reimbursement problems with off-label medicines for rare 
neuromuscular diseases are being inventoried among neuromuscular 
specialists and patients with neuromuscular disease in the Netherlands. A 
consensus meeting will be organized to define legal, ethical and scientific 
preconditions for formalizing and sustaining an n-of-one trial service. An 
electronic data registry system for n-of-one trials will be designed, and 
several protocols will be written for specific trials to be performed in a pilot 
implementation of the n-of-one trial service.
implications: If an n-of-one trial service is successfully designed, a 
subsequent project can pilot trials for off-label neuromuscular indications 
and eventually others. Societal acceptance of n-of-one evidence may also 
stimulate development of genomic therapies tailored to rare genotypes.
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